Oxlumo
E446847
Oxlumo is an RNA interference (RNAi) therapeutic used to treat primary hyperoxaluria type 1 by reducing hepatic oxalate production.
All labels observed (1)
| Label | Occurrences |
|---|---|
| Oxlumo canonical | 1 |
How this entity was disambiguated
This entity first appeared as the object of triple T4492415 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: Oxlumo Context triple: [Alnylam Pharmaceuticals, develops, Oxlumo]
-
A.
Ixil
Ixil is a Mayan language spoken primarily by the Ixil people in the highlands of Guatemala.
-
B.
Yaxhá
Yaxhá is an ancient Maya archaeological site in northern Guatemala known for its large ceremonial complexes and scenic setting beside Lake Yaxhá.
-
C.
Tonalá
Tonalá is a municipality and city in the Guadalajara metropolitan area of Jalisco, Mexico, known for its traditional pottery and handicrafts.
-
D.
Marangona
Marangona is the largest and most famous bell of St Mark's Campanile in Venice, traditionally used to mark the beginning and end of the working day and to signal important civic events.
-
E.
Naiche
Naiche was the last hereditary chief of the Chiricahua Apache and a prominent leader during the final phase of the Apache resistance against the United States.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: Oxlumo Target entity description: Oxlumo is an RNA interference (RNAi) therapeutic used to treat primary hyperoxaluria type 1 by reducing hepatic oxalate production.
-
A.
Ixil
Ixil is a Mayan language spoken primarily by the Ixil people in the highlands of Guatemala.
-
B.
Yaxhá
Yaxhá is an ancient Maya archaeological site in northern Guatemala known for its large ceremonial complexes and scenic setting beside Lake Yaxhá.
-
C.
Tonalá
Tonalá is a municipality and city in the Guadalajara metropolitan area of Jalisco, Mexico, known for its traditional pottery and handicrafts.
-
D.
Marangona
Marangona is the largest and most famous bell of St Mark's Campanile in Venice, traditionally used to mark the beginning and end of the working day and to signal important civic events.
-
E.
Naiche
Naiche was the last hereditary chief of the Chiricahua Apache and a prominent leader during the final phase of the Apache resistance against the United States.
- F. None of above. chosen
Statements (47)
| Predicate | Object |
|---|---|
| instanceOf |
RNA interference therapeutic
ⓘ
drug ⓘ prescription medicine ⓘ small interfering RNA ⓘ |
| affectsOrgan | liver ⓘ |
| approvedBy |
European Medicines Agency
ⓘ
U.S. Food and Drug Administration ⓘ
linked to:
Food and Drug Administration
|
| belongsToPathway | RNA interference pathway ⓘ |
| developedBy | Alnylam Pharmaceuticals ⓘ |
| hasApprovalType | orphan drug ⓘ |
| hasATCCode | A16AX19 ⓘ |
| hasCommonAdverseEffect |
abdominal pain
ⓘ
headache ⓘ injection site reactions ⓘ nasopharyngitis ⓘ |
| hasDosageForm | solution for injection ⓘ |
| hasDosingFrequency |
every three months for maintenance (weight-dependent)
ⓘ
monthly ⓘ |
| hasDrugClass |
RNAi therapeutic
ⓘ
siRNA targeting glycolate oxidase ⓘ |
| hasGenericName | lumasiran ⓘ |
| hasInternationalNonproprietaryName | lumasiran ⓘ |
| hasMolecularTarget | HAO1 gene product pathway ⓘ |
| hasRegulatoryStatus | prescription only ⓘ |
| hasTherapeuticArea |
metabolic disorders
ⓘ
nephrology ⓘ |
| indicatedFor |
PH1
ⓘ
primary hyperoxaluria type 1 ⓘ |
| inhibitsExpressionOf | glycolate oxidase ⓘ |
| isAdministeredTo |
adult patients
ⓘ
pediatric patients ⓘ |
| isContraindicatedIn | patients with known hypersensitivity to lumasiran or excipients ⓘ |
| isFirstInClass | RNAi therapeutic for primary hyperoxaluria type 1 ⓘ |
| isUsedAs | chronic therapy ⓘ |
| marketingAuthorizationHolder | Alnylam Pharmaceuticals ⓘ |
| mechanismOfAction | RNA interference–mediated degradation of HAO1 mRNA ⓘ |
| reduces |
glycolate oxidase activity
ⓘ
hepatic oxalate production ⓘ plasma oxalate levels ⓘ urinary oxalate levels ⓘ |
| resultsIn |
decreased oxalate biosynthesis
ⓘ
increased glycolate levels ⓘ |
| routeOfAdministration | subcutaneous injection ⓘ |
| targets |
HAO1 mRNA
ⓘ
hydroxyacid oxidase 1 mRNA ⓘ |
| treats |
hyperoxaluria-related systemic oxalosis
ⓘ
recurrent kidney stones due to PH1 ⓘ |
How these facts were elicited
The pipeline generated the facts above by prompting gpt-5.1 with this entity's name + description and the instruction below.
Instruction
You are a knowledge base construction expert. Given a subject entity and a description of it, return factual statements that you know for the subject as a JSON list of dictionaries(triples), where keys must be "subject", "predicate" and "object". The number of facts may be very high, between 25 to 50 or more, for very popular subjects. For less popular subjects, the number of facts can be very low, like 5 or 10. # Requirements - If you don't know the subject at all, return an empty list. - If the subject is not a named entity, return an empty list. - Include at least one triple where predicate is "instanceOf". - Do not get too wordy. - Separate several objects into multiple triples with one object.
Input
Subject: Oxlumo Description of subject: Oxlumo is an RNA interference (RNAi) therapeutic used to treat primary hyperoxaluria type 1 by reducing hepatic oxalate production.
Referenced by (1)
Full triples — surface form annotated when it differs from this entity's canonical label.